Yasuyuki Kakurai

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma

Koji Izutsu, Shinichi Makita, Kisato Nosaka et al. · Blood · 2022 · 156 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas

Atsushi Natsume, Yoshiki Arakawa, Yoshitaka Narita et al. · Neuro-Oncology · 2022 · 84 citations · Full text

Medicine, Oncology, Pharmacology +8

Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study

Shunji Takahashi, Yutaka Fujiwara, Kenji Nakano et al. · Cancer Science · 2021 · 72 citations · Full text

Medicine, Oncology, Pharmacology +15

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors

Kohei Shitara, Taroh Satoh, Satoru Iwasa et al. · Journal for ImmunoTherapy of Cancer · 2019 · 32 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive <i>IDH1</i> mutant gliomas.

Atsushi Natsume, Toshihiko Wakabayashi, Yasuji Miyakita et al. · Journal of Clinical Oncology · 2019 · 24 citations

Medicine, Oncology, Pharmacology +15